Marvel Biosciences Corp (TSXV:MRVL) Financings

Marvel Biosciences Corp

Financings

RaiseDateIn US dollars
Private placement of units
Closed: C$1.6M raised · C$0.15 a unit · 1 warrant at C$0.2 for 12 months · Raymond James Ltd. +5
Dealers: Raymond James Ltd. (finder), Canaccord Genuity Corp. (finder), Research Capital Corporation (finder), Acumen Capital Finance Partners Limited (finder), Hampton Securities (finder), Leede Financial Inc. (finder)
Use of proceeds: Deposit for phase 1 clinical trials of lead compound MB-204, general and administrative expenses and general working capital
Sep 29, 2026US$1.13M
Unsecured convertible debentures
Closed: C$500,000 raised · C$0.17 · free to trade Aug 17, 2026
Use of proceeds: Drug formulation, toxicology studies and general working capital
Apr 17, 2026US$365,738
Warrant exercise of common share purchase warrants
Announced: Warrants at C$0.15
Oct 3, 2025
Private placement of units
Closed: C$1.02M raised · C$0.125 a unit · 1 warrant at C$0.175 for 24 months · Raymond James Ltd. +5
Dealers: Raymond James Ltd. (finder), Canaccord Genuity Corp. (finder), Acumen Capital Finance Partners Limited (finder), Wood Gundy (finder), Abinvest Corporation (finder), Abingdon Capital Corp. (finder)
Use of proceeds: Drug formulation, toxicology studies and general working capital
May 12, 2025
Private placement of common shares
Cancelled: C$1.94M–C$2.5M · C$0.15 a share · Abingdon Capital
Dealers: Abingdon Capital (finder)
Use of proceeds: Deposit for phase 1 clinical trials of lead compound MB-204, general and administrative expenses and general working capital
May 2, 2025US$1.35M

Read by 6ix AI from the company's releases